• Patent Title: Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
  • Application No.: US16047740
    Application Date: 2018-07-27
  • Publication No.: US10683295B2
    Publication Date: 2020-06-16
  • Inventor: Hamid R. HoveydaGuillaume DutheuilGraeme Lovat FraserMarie-Odile RoyMohamed El BousmaquiFrederic Batt
  • Applicant: Ogeda SA
  • Applicant Address: BE Gosselies
  • Assignee: Ogeda SA
  • Current Assignee: Ogeda SA
  • Current Assignee Address: BE Gosselies
  • Agency: McCarter & English, LLP
  • Agent Maria Laccotripe Zacharakis; Xin Zhang
  • Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@28dd12e com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@50c72408 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@52cfb060 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@10f835b3
  • Main IPC: C07D241/38
  • IPC: C07D241/38 C07D487/04
Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
Abstract:
The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
Information query
Patent Agency Ranking
0/0